Head-to-head comparisons of medication uses, side effects, warnings, and more.
Rinvoq (upadacitinib)
Dupixent (dupilumab)
Rinvoq (upadacitinib)
Dupixent (dupilumab)
Summary of Rinvoq vs. Dupixent
Summary for JAK inhibitor
Prescription only
Rinvoq (upadacitinib) is a Janus kinase (JAK) inhibitor. It's used to treat certain inflammatory conditions, such as rheumatoid arthritis (RA), ulcerative colitis (UC), and eczema (atopic dermatitis). But it's not a first-choice option and typically only prescribed when other treatments haven't worked well. Rinvoq (upadacitinib) is taken by mouth, usually once daily. It's available as an extended-release tablet (Rinvoq) and an oral solution (Rinvoq LQ), but the two formulations aren't interchangeable. Side effects include a higher risk of infections, acne, and nausea.
Summary for Interleukin antagonist
Prescription only
Dupixent (dupilumab) is an injection that helps treat certain inflammatory conditions. This includes eczema, asthma, and chronic obstructive pulmonary disease (COPD), among others. It's a biologic medication known as an interleukin antagonist that lowers inflammation. Dupixent (dupilumab) comes as prefilled pens and prefilled syringes. It's injected under the skin of the belly or thighs (or in the back of the upper arm with someone's help). The dosing schedule depends on the condition you have, your age, and your weight. It's injected either every week, every 2 weeks, or every 4 weeks. Side effects include injection site reactions and eye problems.
Indications of Rinvoq vs. Dupixent
Indications for
Moderate-to-severe inflammatory conditions in which other treatments haven't worked: